-
Mashup Score: 0Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab - 2 year(s) ago
Objective The anti-α4β7 integrin antibody vedolizumab is administered at a fixed dose for the treatment of IBDs. This leads to a wide range of serum concentrations in patients and previous studies had suggested that highest exposure levels are associated with suboptimal clinical response. We aimed to determine the mechanisms underlying these non-linear exposure-efficacy characteristics of…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 4Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab - 2 year(s) ago
Objective The anti-α4β7 integrin antibody vedolizumab is administered at a fixed dose for the treatment of IBDs. This leads to a wide range of serum concentrations in patients and previous studies had suggested that highest exposure levels are associated with suboptimal clinical response. We aimed to determine the mechanisms underlying these non-linear exposure-efficacy characteristics of…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper "Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab" via https://t.co/Enx1bhBnlA #IBD #Vedolizumab https://t.co/1JMzWJDiPL
-
-
Mashup Score: 0Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab - 2 year(s) ago
Objective The anti-α4β7 integrin antibody vedolizumab is administered at a fixed dose for the treatment of IBDs. This leads to a wide range of serum concentrations in patients and previous studies had suggested that highest exposure levels are associated with suboptimal clinical response. We aimed to determine the mechanisms underlying these non-linear exposure-efficacy characteristics of…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper "Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab" via https://t.co/Enx1bhBnlA #IBD #Vedolizumab https://t.co/Hzw52KF7eQ
-
-
Mashup Score: 0Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab - 2 year(s) ago
Objective The anti-α4β7 integrin antibody vedolizumab is administered at a fixed dose for the treatment of IBDs. This leads to a wide range of serum concentrations in patients and previous studies had suggested that highest exposure levels are associated with suboptimal clinical response. We aimed to determine the mechanisms underlying these non-linear exposure-efficacy characteristics of…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper "Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab" via https://t.co/Enx1bhBnlA #IBD #Vedolizumab https://t.co/dvG6hdDwja
-
-
Mashup Score: 0Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab - 2 year(s) ago
Objective The anti-α4β7 integrin antibody vedolizumab is administered at a fixed dose for the treatment of IBDs. This leads to a wide range of serum concentrations in patients and previous studies had suggested that highest exposure levels are associated with suboptimal clinical response. We aimed to determine the mechanisms underlying these non-linear exposure-efficacy characteristics of…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper "Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab" via https://t.co/Enx1bhBnlA #IBD #Vedolizumab https://t.co/bSBp0cU62m
-
-
Mashup Score: 0Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab - 2 year(s) ago
Objective The anti-α4β7 integrin antibody vedolizumab is administered at a fixed dose for the treatment of IBDs. This leads to a wide range of serum concentrations in patients and previous studies had suggested that highest exposure levels are associated with suboptimal clinical response. We aimed to determine the mechanisms underlying these non-linear exposure-efficacy characteristics of…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper "Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab" via https://t.co/Enx1bhBnlA #IBD #Vedolizumab https://t.co/p0o8qB4NZf
-
-
Mashup Score: 2Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab - 2 year(s) ago
Objective The anti-α4β7 integrin antibody vedolizumab is administered at a fixed dose for the treatment of IBDs. This leads to a wide range of serum concentrations in patients and previous studies had suggested that highest exposure levels are associated with suboptimal clinical response. We aimed to determine the mechanisms underlying these non-linear exposure-efficacy characteristics of…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper "Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab" via https://t.co/Rm5UrD9aaK #IBD #Vedolizumab https://t.co/E9pJnakvWz
-
-
Mashup Score: 0
SAN DIEGO — Vedolizumab and ustekinumab associated with a lower risk for infection-related hospitalizations compared with anti-tumor necrosis factor agents in patients who initiated inflammatory bowel disease therapy at an older age. “It used to be thought that IBD becomes a milder disease with age and, therefore, there never was a tremendous investment in better understanding modern
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI from @DDWMeeting 2022: “For older adults with greater #morbidity, #vedolizumab and #ustekinumab confer a lower risk for infection-related hospitalizations compared with anti-TNF agents,” @bkocharmd #IBD #DDW2022 #GITwitter https://t.co/jDOWw1Mmag
-
-
Mashup Score: 0
SAN DIEGO — Vedolizumab and ustekinumab associated with a lower risk for infection-related hospitalizations compared with anti-tumor necrosis factor agents in patients who initiated inflammatory bowel disease therapy at an older age. “It used to be thought that IBD becomes a milder disease with age and, therefore, there never was a tremendous investment in better understanding modern
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#Vedolizumab and #ustekinumab associated with a lower risk for infection-related #hospitalizations compared with anti-tumor necrosis factor agents in patients who initiated #IBD therapy at an older age @bkocharmd @DDWMeeting #DDW2022 #GITwitter https://t.co/jDOWw1Mmag
-
-
Mashup Score: 0IV vedolizumab effectively treats chronic pouchitis in UC - 2 year(s) ago
Among patients with ulcerative colitis, IV vedolizumab safely and effectively treated chronic pouchitis following ileal pouch-anal anastomosis, according to research presented at the Congress of European Crohn’s and Colitis Organization.
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI: "[#IV #vedolizumab] showed consistent benefits across clinical, endoscopic and histological endpoints; there was a concomitant improvement in the health-related quality of life," Simon Travis, DPhil, FRCP, @UniofOxford #ECCO2022 #GITwitter https://t.co/pbEm7GmarY
-
#GUTImage from the paper "Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab" via https://t.co/Enx1bhBnlA #IBD #Vedolizumab https://t.co/nWH1KNRhhm